Current Market Information

Last Trade Price (LTP) 10.60 Last Trade Date 11 August, 2025 Change 0.00 % Open Price 10.60 Day's Range 10.50 - 10.60     Total Trade 2 Total Volume 1000 Close Price 10.60 Yesterday Close Price 10.60 Market Capital in BDT (mn) 1446.900

Contact Information

Designation Name Mobile Number Email Chairman Mrs. Silvana Mirza MD Mr. MOhammad Enayet Ullah(c.c) CFO Md. Abul Kasem Company Secretary Md. Iqbal Hossain 01711891686 hossainiqbal.md123@gmail.com Office Address House # 65, Road # 8/A (New), Dhanmondi, Dhaka-1209. Phone : 02-55000692 Fax : 02-55000693 Email : share@silvapharma.com, hossainiqbal.md123@gmail.com Website : http://www.silvapharma.com Factory Address 1.Main Road, Maijdee Court, Noakhali, Bangladesh.

Basic Information

Authorized Capital in BDT* (mn) 1,500.00 Paid-up Capital in BDT* (mn) 1,365.00 Face Value 10 Paid up Share 136500000     Market Lot 1 Sector PHARMA & CHEMICALS Market Category B

Other Information

Listing Year 2018 Debut Trade Date 10 October, 2018 Type of Instrument     52 Week's Range 8.80 - 16.80 Year End 30 June Reserve / Surplus(mn) 890.95 Remarks Note

Share Holding Percentage

Sponsor/Director Govt. Institute Foreign Public As on 31-Jul, 2025 45.21 0 16.2 0.01 38.58 As on 31-May, 2025 45.21 0 15.95 0.01 38.83 As on 30-Apr, 2025 45.21 0 15.99 0.01 38.79 As on 30-Jun, 2025 (year ended) 45.21 0 16.84 0.01 37.94     Remarks Note     Credit Rating Status Credit Rating Year Long Term Short Term Outlook Validity Date Credit Rating Company Dec 11, 2024 A3 ST-1 Stable Dec 31, 2025 Credit Rating Agency of Bangladesh Ltd. (CRAB) Dec 26, 2023 A3 ST-1 Stable Dec 31, 2024 Credit Rating Agency of Bangladesh Ltd. (CRAB) Dec 29, 2022 A3 ST-3 Stable Dec 28, 2023 Credit Rating Agency of Bangladesh Ltd. (CRAB)         Half Year End (HY) Information  202412 HY Net Turnover(mn)  201.63 HY Net Profit after tax(mn)  -59.04 HY EPS  -0.43  AGM Information   AGM Date  30 December, 2024 Record Date  01 December, 2024 Dividend(%)  1.00 (Cash dividend for shareholders excluding the Sponsors and Directors- June 2024) Bonus Issue  5% 2019

   

Financial Performance
Performance Year	Basic EPS Based On		Basic EPS (restated) Based On		Net Asset Value Per Share	Restated Net Asset Value Per Share	Net Profit After Tax(mn)		% Dividend	% Dividend Yield
	Continuous operations	Including Extra-Ordinary Income	Continuous operations	Including Extra-Ordinary Income			Continuous operations	Including Extra-Ordinary Income
2024	-0.47	0	0	0	16.53	0	-64.48	0	1%C	6.99
2023	0.24	0	0	0	17.1	0	33.08	0	1%C	0.44
2022	0.75	0	0	0	17.03	0	102.26	0	3%C	0.01
2021	0.88	0	0	0	16.63	0	119.85	0	5%C	2.54
2020	0.87	0	0	0	16.1	0	118.94	0	5%C	2.73

Financial Statements
Quarterly Financial Statement	https://silvapharma.com/investors/quarterly-reports/
Price Sensitive Information	https://silvapharma.com/investors/price-sensitive-information/

Close Price and Traded Volume Graph
Click here to view 1 month graph	Click here to view 3 month graph	Click here to view 6 month graph
Form	To